Zobrazeno 1 - 10
of 37
pro vyhledávání: '"Saad Z. Usmani"'
Autor:
Meletios A. Dimopoulos, Albert Oriol, Hareth Nahi, Jesus San-Miguel, Nizar J. Bahlis, Saad Z. Usmani, Neil Rabin, Robert Z. Orlowski, Kenshi Suzuki, Torben Plesner, Sung-Soo Yoon, Dina Ben Yehuda, Paul G. Richardson, Hartmut Goldschmidt, Donna Reece, Tahamtan Ahmadi, Xiang Qin, Wendy Garvin Mayo, Xue Gai, Jodi Carey, Robin Carson, Philippe Moreau
Publikováno v:
Journal of Clinical Oncology. 41:1590-1599
PURPOSE With the initial analysis of POLLUX at a median follow-up of 13.5 months, daratumumab in combination with lenalidomide and dexamethasone (D-Rd) significantly prolonged progression-free survival versus lenalidomide and dexamethasone (Rd) alone
Autor:
Thomas Martin, Saad Z. Usmani, Jesus G. Berdeja, Mounzer Agha, Adam D. Cohen, Parameswaran Hari, David Avigan, Abhinav Deol, Myo Htut, Alexander Lesokhin, Nikhil C. Munshi, Elizabeth O'Donnell, A. Keith Stewart, Jordan M. Schecter, Jenna D. Goldberg, Carolyn C. Jackson, Tzu-Min Yeh, Arnob Banerjee, Alicia Allred, Enrique Zudaire, William Deraedt, Yunsi Olyslager, Changwei Zhou, Lida Pacaud, Deepu Madduri, Andrzej Jakubowiak, Yi Lin, Sundar Jagannath
Publikováno v:
Journal of Clinical Oncology. 41:1265-1274
PURPOSE CARTITUDE-1, a phase Ib/II study evaluating the safety and efficacy of ciltacabtagene autoleucel (cilta-cel) in heavily pretreated patients with relapsed/refractory multiple myeloma, yielded early, deep, and durable responses at 12 months. He
Autor:
Arnob Banerjee, Yunsi Olyslager, Carolyn C. Jackson, Saad Z. Usmani, Xiaoling Wu, Mounzer Agha, Yi Lin, Tzu-Min Yeh, Adam D. Cohen, Jesus G. Berdeja, Marlene Carrasco-Alfonso, Muhammad Akram, Deepu Madduri, Alicia J. Allred, Andrzej Jakubowiak, William Deraedt, Thomas G. Martin, Sundar Jagannath, Enrique Zudaire, Parameswaran Hari
Publikováno v:
Journal of Clinical Oncology. 39:8005-8005
8005 Background: CARTITUDE-1 (NCT03548207) is a phase 1b/2 study evaluating ciltacabtagene autoleucel (cilta-cel; JNJ-68284528), a CAR T-cell therapy with two BCMA–targeting single-domain antibodies, in patients (pts) with R/R MM. Here, we report u
Autor:
Saad Z. Usmani, Emily Baldrige, Ashley Sumrall, Seungjean Chai, Brittany K. Ragon, Peter M. Voorhees, Sally Jeanne Trufan, Courtney Schepel, Jimmy J. Hwang, Edward S. Kim, Michael R. Grunwald, Derek Raghavan, Edward A. Copelan, Zainab Shahid, Nilanjan Ghosh, Antoinette R. Tan, Laura W. Musselwhite
Publikováno v:
Journal of Clinical Oncology. 39:e18753-e18753
e18753 Background: Cancer patients are more susceptible to developing severe disease associated with SARS-CoV-2 infection. Herein, data from a high-volume cancer center is presented highlighting risk factors associated with hospitalization with COVID
Autor:
Deepa Dongarwar, Hamisu M. Salihu, LaQuisa Hill, Carlos A. Ramos, Saad Z. Usmani, Helen E. Heslop, Samer Al Hadidi, George Carrum, Premal Lulla, Rammurti T. Kamble
Publikováno v:
Journal of Clinical Oncology. 39:e18512-e18512
e18512 Background: Multiple Myeloma (MM) is the most common hematologic malignancy in Black Americans. Incidence and death rates for MM in Black Americans are more than double those in Whites. Our study aimed to evaluate trends of all cause in-hospit
Autor:
Peter M. Voorhees, Ashley Sumrall, Saad Z. Usmani, Laura W. Musselwhite, Nilanjan Ghosh, Courtney Schepel, Brittany K. Ragon, Kathryn Finch Mileham, Michael R. Grunwald, Jimmy J. Hwang, Derek Raghavan, Zainab Shahid, Seungjean Chai, Edward A. Copelan, Antoinette R. Tan, Emily Baldrige, Sally Jeanne Trufan
Publikováno v:
Journal of Clinical Oncology. 39:e18776-e18776
e18776 Background: SARS-CoV-2 virus has been shown to persist in respiratory tract in immunocompromised patients. However, such data are lacking for both asymptomatic and symptomatic SARS-CoV-2 infection in cancer patients. We share our single center
Autor:
Saad Z. Usmani, Myra M. Robinson, Reed Friend, Mauricio Pineda-Roman, Shebli Atrash, Jordan Robinson, Peter M. Voorhees, Barry Paul, Ami Ndiaye, James T. Symanowski, Manisha Bhutani
Publikováno v:
Journal of Clinical Oncology. 39:e20011-e20011
e20011 Background: Multiple Myeloma (MM) is an incurable malignancy of terminally differentiated plasma cells. The combination of pomalidomide/dexamethasone with either daratumumab or isatuximab is FDA approved for relapsed refractory multiple myelom
Autor:
Concetta Crivera, Satish Valluri, Carolyn C. Jackson, Anil Londhe, Joris Diels, Kwee Yong, Saad Z. Usmani, Yunsi Olyslager, Katja Weisel, Martin Vogel, Amrita Krishnan, Keqin Qi, Maneesha Mehra, Jordan M. Schecter, Arnob Banerjee, Sundar Jagannath, Sandhya Nair, Jesus G. Berdeja, Thomas G. Martin
Publikováno v:
Journal of Clinical Oncology. 39:8045-8045
8045 Background: Pts with RRMM who are triple-class exposed (to immunomodulatory drugs [IMiDs], proteasome inhibitors [PIs] and an anti-CD38 antibody) cycle through multiple salvage regimens with progressively worse outcomes. CARTITUDE-1 (NCT03548207
Autor:
Amrita Krishnan, Ajai Chari, Jesús F. San-Miguel, Tara Stephenson, Maria-Victoria Mateos, Niels W.C.J. van de Donk, Laura Rosiñol, Lotfi Benboubker, Albert Oriol, Hareth Nahi, Alfred L. Garfall, Lionel Karlin, Manisha Bhutani, Suzette Girgis, Saad Z. Usmani, Raluca Verona, Arnob Banerjee, Jenna D. Goldberg, Lixia Pei
Publikováno v:
Journal of Clinical Oncology. 39:8007-8007
8007 Background: BCMA-targeted immunotherapies offer considerable promise for relapsed/refractory MM. Teclistamab (JNJ-64007957) is a BCMA × CD3 bispecific IgG4 antibody that redirects CD3+ T cells to BCMA-expressing MM cells. We present updated res
Autor:
Thomas G. Martin, Shaji Kumar, Natalie S. Callander, Jordan M. Schecter, Parameswaran Hari, Arnob Banerjee, Hong Tian, Ravi Vij, Jesus G. Berdeja, Yi Lin, Saurabh Chhabra, Luciano J. Costa, Carolyn C. Jackson, Satish Valluri, Ankit Kansagra, Jennifer Marino, Yubin Kang, Sundar Jagannath, Saad Z. Usmani
Publikováno v:
Journal of Clinical Oncology. 39:8030-8030
8030 Background: CARTITUDE-1 is a single arm study of Ciltacabtagene autoleucel (cilta-cel; JNJ-68284528) anti-BCMA CAR-T cell therapy in US patients (pts) with relapsed multiple myeloma (RRMM) refractory to both IMiD and proteasome inhibitor (PI) or